Combo Product Firms Want Simpler Adverse Event Reporting Structure
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed adverse event reporting requirements for combination products should be rewritten to simplify the way events are reported when multiple manufacturers are involved, firms say
You may also be interested in...
FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules
FDA’s prescription drug regulations in the works include rules on generic drug labeling, compounding, bioequivalence reports and safety reporting for combination products.
Drug Shortage Rules Surface In Latest FDA Regulatory Agenda
FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.
Combination Products Office Finalizing Manufacturing, Adverse Event Rules
FDA says final rules on good manufacturing practices and adverse event reporting for combination products could be out as early as this fall.